Michael Wang, MDAssistant Professor of Medicine, Department of LeukemiaThe University of Texas MD Anderson Cancer Centerlong bio placeholder RelatedMantle Cell LymphomaThis New MCL Combination Treatment Is Practice ChangingDr. Michael Wang of MD Anderson Cancer Center discuss the results a phase 3 study of older mantle cell lymphoma patients when ibrutinib (Imbruvica) is combined with the current standard of care therapy. Mantle Cell LymphomaThis New MCL Combination Treatment Is Practice ChangingDr. Michael Wang of MD Anderson Cancer Center discuss the results a phase 3 study of older mantle cell lymphoma patients when ibrutinib (Imbruvica) is combined with the current standard of care therapy.
